[225Ac]Ac-PSMA-617 mutational landscape in circulating tumor DNA (ctDNA): early clinical outcome prediction in metastatic castration-resistant prostate cancer

被引：0
|
作者：
Amghar, M. [1 ]
Rausch, T. [2 ]
Hielscher, T. [1 ]
Ozgur, H. [2 ]
Roscher, M. [1 ]
Bauder-Wuest, U. [1 ]
Schick, M. [1 ]
Remde, Y. [1 ]
Bakos, G. [1 ]
Schaefer, M. [1 ]
Bruchertseifer, F. [3 ]
Morgenstern, A. [3 ]
Benes, V. [2 ]
Kratochwil, C. [4 ]
Benesova-Schaefer, M. [1 ]
机构：
[1] DKFZ, Heidelberg, Germany
[2] EMBL, Heidelberg, Germany
[3] Joint Res Ctr JRC, European Commiss, Karlsruhe, Germany
[4] Univ Hosp, Dept Nucl Med, Heidelberg, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-719
引用
收藏
页码：S326 / S326
页数：1
相关论文
共 50 条
  • [21] Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer
    Perrone, Elisabetta
    Giordano, Alessandro
    Calcagni, Maria Lucia
    Leccisotti, Lucia
    Moretti, Roberto
    Eismant, Aleksandr
    Ghai, Kriti
    Parkar, Tanay
    Mishra, Aditi
    Heidenreich, Axel
    Wirtz, Ralph M.
    Mueller, Joerg
    Greifenstein, Lukas
    Baum, Richard P.
    CANCERS, 2025, 17 (03)
  • [22] Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
    Ling, Sui Wai
    de Blois, Erik
    Hooijman, Eline
    van der Veldt, Astrid
    Brabander, Tessa
    PHARMACEUTICS, 2022, 14 (10)
  • [23] Plasma circulating tumor DNA (ctDNA) based clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
    Kohli, Manish
    Tan, Winston
    Zheng, Tiantian
    Wang, Amy
    Huo, Yelia
    Montesinos, Carlos
    Wong, Calvin
    Du, Pan
    Jia, Shidong
    Yu, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu] Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
    Fettke, Heidi
    Kostos, Louise
    Buteau, James
    Steen, Jason A.
    Medhurst, Elizabeth
    Haskali, Mo B.
    Murphy, Declan
    Docanto, Maria
    Bukczynska, Patricia
    Ng, Nicole
    Sandhu, Shahneen
    Foroughi, Siavash
    Furic, Luc
    Nguyen-Dumont, Tu
    Hofman, Michael S.
    Azad, Arun A.
    CANCER RESEARCH, 2023, 83 (07)
  • [25] Survival outcomes of patients with metastatic castration resistant prostate cancer receiving 225Ac-PSMA-617 radioligand therapy
    Bal, Chandrasekhar
    Ballal, Sanjana
    Yadav, Madhav
    Sahoo, Ranjit
    Tripathi, Madhavi
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [26] 225Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
    Ballal, Sanjana
    Yadav, Madhav P.
    Sahoo, Ranjit K.
    Tripathi, Madhavi
    Dwivedi, Sada N.
    Bal, Chandrasekhar
    PROSTATE, 2021, 81 (09): : 580 - 591
  • [27] AcTION: A phase 1 study of [225Ac]Ac-PSMA-617 in men with PSMA-positive prostate cancer with or without prior [177Lu]Lu-PSMA-617 radioligand therapy
    Sathekge, M.
    Crumbaker, M.
    Joshua, A. M.
    Bruchertseifer, F.
    Kreisl, T.
    Emineni, S.
    Wehbe, J.
    Korn, M.
    Morgenstern, A.
    Emmett, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S152 - S153
  • [28] Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Khalaf, Daniel
    Annala, Matti
    Beja, Kevin
    Vandekerkhove, Gillian
    Zulfiqar, Muhammad
    Finch, Daygen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [29] Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617:Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
    Kratochwil, Clemens
    Bruchertseifer, Frank
    Rathke, Hendrik
    Hohenfellner, Markus
    Giesel, Frederik L.
    Haberkorn, Uwe
    Morgenstern, Alfred
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (05) : 795 - 802
  • [30] Clinical Experience on 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration Resistant Prostate Cancer Patients: Safety and Efficacy Results
    Bal, Chandrasekhar
    Yadav, Madhav
    Ballal, Sanjana
    Tripathi, Madhavi
    Sahoo, Ranjit
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
12345